Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia

Summary

Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. In addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (EGCG), including SARS-CoV-2. In previous studies, we found that EGCG can prevent and cure radiation- induced normal tissue damage in tumor patients. In clinical studies, we found that EGCG can prevent and treat radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation oral mucositis with high safety. At the same time, the phase I clinical trial designed by us has confirmed the safety and efficacy of EGCG in the treatment of interstitial pneumonia.

Timeline

Start

2023-06-05

Primary completion

2024-06-02

Completion

2024-07-02

Outcome

Met primary endpoint

paper The EGCG group showed significantly greater CT improvement (P = 0.004) PMID 41549240 ↗

Publications

• Zhu W, Jia L, Qiao Q, Li X, Peng X, Meng X, Kong L, Zhao H. Efficacy and safety of 7-day aerosolized epigallocatechin-3-gallate in oncologic patients with COVID-19 pneumonia. BMC Cancer. 2026 Jan 19;26(1):235. doi: 10.1186/s12885-026-15553-x.

Drugs

Indications